Stage II Colon Cancer, Stage III Colon Cancer
Conditions
Keywords
colon cancer, high-risk stage, curative resection, adjuvant chemotherapy
Brief summary
According to general medical guidelines, adjuvant chemotherapy is used after curative resection of high-risk stage II or III primary colon cancer. However, there exist limitations using clinical trial data acquired from highly selected subjects in a controlled environment. For example, patients aged over 70 years old were in many cases excluded from clinical trials resulting in insufficient data on the efficacy of therapies including oxaliplatin in aged patients, and the source data of the medical guidelines did not fully reflect the conditions of Korean patients. In addition, suggestions are continuously being submitted for existing therapies with modified administration periods and methods with the aim to search for the optimum effect over side effects. Discussions are also held on meta analyses results that imply the need to apply slightly different approaches through small groups of patient and disease factors. As there are more diverse adjuvant therapy protocols that can be applied to post-surgery colon cancer patients, it is necessary to figure out the patterns of adjuvant chemotherapies actually used in Korean medical practices. Also, in order to complement the limitation of external validity of the existing base clinical data, a multifaceted exploratory analysis will be conducted by making follow-up observations on patterns, prognosis results, quality of life, adverse effects, etc. of post-surgery adjuvant chemotherapies actually used in around 30 sites in Korea under the noninterventional observational study conditions.
Detailed description
\[Overview\] Investigators will obtain voluntary consent for participation in this study from patients with high-risk stage II or stage III colon cancer who require or are planning to receive adjuvant chemotherapy after curative resection. Patients who provided written consent for using their personal information and who satisfy inclusion/exclusion criteria will be given a study enrollment number. Among the predefined study-relevant data, available data on these patients will be collected in the case report forms (CRF) until the study is completed. \[Follow-up observation schedule and the scope of data collection\] Since this study is an observational study, data collection in the CRF will be restricted to the data created only from usual treatment practices and there will be no separate test or additional drug administration for the study. However, subjects will be asked to complete questionnaire to evaluate their quality of life at the following time points: baseline, Month 3 (13 weeks ± 2 weeks), Month 6 (26 weeks ± 2 weeks), Month 12 (52 weeks ± 4 weeks), Month 24 (104 weeks ± 8 weeks), Month 36 (156 weeks ± 8 weeks). For subjects who drop out from the study or in case of disease event (relapse, metastasis or new primary malignant tumor), the questionnaire will be conducted at the time of drop-out or disease event. Survival of all subjects (including those who drop out from the study or whose disease event is confirmed) will be checked every 6 months after adjuvant chemotherapy started. Among the data created from the subjects on their visits for treatment, the following data will be collected for the purpose of this study. * Demographics of the subjects. * Colon cancer information (diagnosis information, risk factors, surgery information). * Whether or not neoadjuvant chemotherapy was conducted. * Underlying disease. * Adjuvant chemotherapy information. * Other concomitant medication (drugs administered for prevention and treatment of OXLIPN, drugs administered for treatment of Grade 3-4 adverse drug reactions/serious adverse drug reactions related to the chemotherapy). * Vital signs, height, and weight. * Performance Status evaluation (ECOG PS). * Geriatric Assessment (KG-7): for subjects ≥ 65 years old. * Quality of Life assessment (FACT-C, FACT/GOG-NTX-12). * Laboratory test results. * Tumor Marker (CEA, CA 19-9) test results. * Molecular genetic test results (MSI \[microsatellite instability\] and/or MMR \[DNA mismatch repair gene\], immunohistochemistry test for protein, KRAS, NRAS, BRAF etc.). * Colonoscopy/CT results. * Disease event (relapse, metastasis or new primary malignant tumor). * Survival of subjects. * Oxaliplatin-induced Peripheral Neuropathy (OXLIPN): Only when oxaliplatin is administered. * Grade 3-4 adverse drug reactions related to chemotherapy (based on CTCAE v.5.0). * Serious adverse drug reactions.
Interventions
None listed
Sponsors
Boryung Pharmaceutical Co., Ltd
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Subjects are given explanations about the study objectives and methods, and will express their consent by signing a written agreement to use their personal information. 2. Male and female adult subjects who are ≥ 19 years old. 3. Subjects are confirmed to have primary colon cancer through histological diagnosis and are at \*high-risk stage II (T3/4, N0M0) or stage III (any T, N1/2, M0). * High-risk stage II is determined when one or more of the following are applicable. 1. Cancer is at T4 stage (stage IIB,IIC); 2. Cancer cell differentiation grade is 3 or 4 (poor histologic grade); 3. Cancer cells are present in lymphatic or blood vessels around the tumor (peritumoral lymphovascular involvement); 4. Ileus was present during surgery (bowel obstruction at presentation); 5. Cancer is at T3 stage with localized perforation or there are indeterminate cancer cells residual on the incisal surface. (T3 lesions with localized perforation or close, indeterminate, or positive margins); or, 6. Cancer cells invaded into the area around the ganglion (perineural invasion). 4. Subjects are decided to require adjuvant chemotherapy including oxaliplatin and/or capecitabine after curative resection (E.g.: FOLFOX, CapeOx or Capecitabine and modified therapies). 5. Subjects' performance status score (ECOG PS) is 2 or lower (0, 1, 2).
Exclusion criteria
1. Subjects are diagnosed with other primary cancers that can influence the treatment or prognosis of primary rectal and colon cancers. 2. Subjects are diagnosed with relapsed or secondary colon cancer. 3. Subjects with Stage 0/1 (Tis/1/2, N0M0) or Stage IV (any T, any N, M1) colon cancer. 4. Subjects who are currently on adjuvant chemotherapy after curative resection. 5. Subjects who are receiving palliative chemotherapy. 6. Pregnant and breast-feeding subjects. 7. Subjects who are currently participating in other clinical trials (clinical trials for drugs or medical devices) or are planning to participate in other clinical trials during the duration of this study. However, subjects participating in a noninterventional observational study or a registry study can participate in this study. 8. Other subjects who are not suitable for study participation upon the investigator's decision.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Type of adjuvant chemotherapy | through adjuvant chemotherapies completion, an average of 24 weeks | Type of adjuvant chemotherapy that were used. |
| Overall Survival (OS) | From date of resection surgery until the date of death, assessed up to 36 months | Time from the date of resection surgery to the date of death. |
| Disease Free Survival (DFS) | From date of resection surgery until the date of first documented progression, assessed up to 36 months | Time from the date of resection surgery to the date of first relapse, |
| Frequency of adjuvant chemotherapy | through adjuvant chemotherapies completion, an average of 12 cycle(FOLFOX: each cycle is 14 days, XELOX or Capacitabine: each cycle is 21 days) | Frequency of adjuvant chemotherapy that were used. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Characteristics of relapsed and metastasis cancers and new primary malignant tumor list. | up to 36 months | Whether locally relapsed, whether metastasis is present, location of metastasis, etc. |
| Quality of Life Assessment (FACT-C) | Baseline, Month 3 (13 weeks ± 2 weeks), Month 6 (26 weeks ± 2 weeks), Month 12 (52 weeks ± 4 weeks), Month 24 (104 weeks ± 8 weeks), Month 36 (156 weeks ± 8 weeks) | Subjects will be asked to complete questionnaires to evaluate their quality of life |
| Quality of Life Assessment (FACT/GOG-NTX-12) | Baseline, Month 3 (13 weeks ± 2 weeks), Month 6 (26 weeks ± 2 weeks), Month 12 (52 weeks ± 4 weeks), Month 24 (104 weeks ± 8 weeks), Month 36 (156 weeks ± 8 weeks) | Subjects will be asked to complete questionnaires to evaluate their quality of life |
Other
| Measure | Time frame | Description |
|---|---|---|
| Adverse drug reactions/serious adverse drug reactions | From the date of adjuvant chemotherapy started until the end of follow-up(36 month) | Overall incidence of grade 3-4 adverse drug reactions/serious adverse drug reactions |
| Performance Status (ECOG) evaluation results | Baseline, Each cycle(FOLFOX: each cycle is 14 days, XELOX or Capacitabine: each cycle is 21 days), Month 3 (13 weeks ± 2 weeks), Month 6 (26 weeks ± 2 weeks), Month 12 (52 weeks ± 4 weeks), Month 24 (104 weeks ± 8 weeks), Month 36 (156 weeks ± 8 weeks) | Frequency and ratio of ECOG evaluation results will be presented by time point. |
| Oxaliplatin Induced Peripheral Neuropathy, OXLIPN | From the date of adjuvant chemotherapy started until the end of follow-up(36 month) | Overall incidence of Oxaliplatin Induced Peripheral Neuropathy, OXLIPN |
| Results on body temperature | Baseline, Each cycle(FOLFOX: each cycle is 14 days, XELOX or Capacitabine: each cycle is 21 days), Month 3 (13 weeks ± 2 weeks), Month 6 (26 weeks ± 2 weeks), Month 12 (52 weeks ± 4 weeks), Month 24 (104 weeks ± 8 weeks), Month 36 (156 weeks ± 8 weeks) | Descriptive statistics will be presented for the results of body temperature by time point. |
| Results on weight | Baseline, Each cycle(FOLFOX: each cycle is 14 days, XELOX or Capacitabine: each cycle is 21 days), Month 3 (13 weeks ± 2 weeks), Month 6 (26 weeks ± 2 weeks), Month 12 (52 weeks ± 4 weeks), Month 24 (104 weeks ± 8 weeks), Month 36 (156 weeks ± 8 weeks) | Descriptive statistics will be presented for the results of weight by time point. |
| Results on pulse | Baseline, Each cycle(FOLFOX: each cycle is 14 days, XELOX or Capacitabine: each cycle is 21 days), Month 3 (13 weeks ± 2 weeks), Month 6 (26 weeks ± 2 weeks), Month 12 (52 weeks ± 4 weeks), Month 24 (104 weeks ± 8 weeks), Month 36 (156 weeks ± 8 weeks) | Descriptive statistics will be presented for the results of pulse by time point. |
| Results on blood pressure | Baseline, Each cycle(FOLFOX: each cycle is 14 days, XELOX or Capacitabine: each cycle is 21 days), Month 3 (13 weeks ± 2 weeks), Month 6 (26 weeks ± 2 weeks), Month 12 (52 weeks ± 4 weeks), Month 24 (104 weeks ± 8 weeks), Month 36 (156 weeks ± 8 weeks) | Descriptive statistics will be presented for the results of blood pressure by time point. |
Countries
South Korea
Outcome results
None listed